louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06282276: Anti-fat Attitudes and Weight Stigma Among Orthopedic Surgeons
Official title: Anti-fat Attitudes and Weight Stigma Among Orthopedic Surgeons and Their Correlation to the Therapeutic Approach to Patients With Obesity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Weight Stigma
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2024-02-28
Enrollment: 150
Sex: ALL
Minimum age (years): 25
Maximum age (years): 72
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 150 orthopedic surgeon's

Brief summary: Evidence shows that anti-fat attitudes and weight stigma are prevalent among healthcare professionals and may affect treatment decisions regarding patients with obesity. The present study aimed to examine the presence of anti-fat attitudes and weight stigma among orthopedic surgeons and their correlation to the therapeutic approach to patients with obesity. In this cross-sectional survey, 150 orthopedic surgeons will complete a web-based questionnaire. the questionnaire is based on Antifat Attitudes Questionnaire (AFA), developed by Crandall in 1994. In addition, the questionnaire will include a questionnaire developed by Bocquier in 200521 to explore weight stigma among physicians.

Detailed description: Data will be collected through an online questionnaire consisting of four parts. Part 1 will gather socio-demographic data using nine items. Part 2 will utilize the Antifat Attitudes Questionnaire (AFA), developed by Crandall in 1994. The questionnaire, comprising 13 items, will assess three subscales:1. "Dislike" measuring explicit antipathy toward fat individuals.2. "Fear of Fat" measuring personal concerns about weight or becoming overweight.3. "Willpower" measuring beliefs about personal control over being overweight. Participants will rate items on a 10-point Likert scale, with higher scores indicating greater anti-fat bias. Part 3 will include a questionnaire developed by Bocquier in 2005 to explore weight stigma among physicians, consisting of 12 items. Participants will rate items on a 6-point Likert scale, with higher scores indicating stronger weight stigma. Part 4 will investigate the therapeutic approach of orthopedic surgeons to patients with obesity using five items. Participants will items on a 6-point Likert scale, with higher scores indicating a stronger preference for a conservative approach.

Eligibility criteria: Inclusion Criteria: orthopedic surgeon age 18 till 80 -

Exclusion Criteria:

-

Primary outcomes:
measure: anti fat attitudes
timeFrame: 3 months
measure: Weight stigma
timeFrame: 3 months
measure: Therapeutic approach
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT07001176: Caffeine, Resistance Exercise and Muscle/Cerebral Oxygenation
Official title: Effect of Acute Caffeine Intake on Muscle and Cerebral Oxygenation During Muscular Strength, Power, and Endurance Performance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Caffeine and Resistance Exercise
Lead sponsor: University of Alcala
Sponsor class: OTHER
First posted: 2025-06-03
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: Introduction: Several studies have evaluated and confirmed the ergogenic effects of acute caffeine intake on sports performance. However, the mechanism responsible for this ergogenic effect remains to be elucidated.

Objectives: This study aims to evaluate the acute effects of caffeine intake on muscle and cerebral oxygen during muscular strength, power, muscle endurance performance. and muscle electrical activity in young adults.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 35 years.
* Body Mass Index (BMI) \&lt; 25 kg/m².
* Resistance-trained individuals (more than 2 years of structured training).
* Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising.
* Participants must be able to perform the tests described in the following section.

Exclusion Criteria:

* History of neuromuscular diseases, heart disease, or conditions that may affect liver or muscle metabolism.
* Use of drugs, stimulants, or sports supplements that could interfere with the dietary supplement used in the study.
* Sedentary habits (less than 150 minutes/week of moderate exercise).
* Having undergone prolonged periods of physical inactivity in the 6 months prior to the study.
* Engaging in strenuous exercise within 48 hours prior to the tests.
* Failure to replicate the same food intake on both experimental days.
* Consumption of caffeine or any other stimulant after 6 pm on the day before the tests, to avoid headaches, discomfort, or lethargy in regular caffeine consumers.

Primary outcomes:
measure: Muscle Oxygenation
timeFrame: Through study completion, an average of 2 weeks
measure: Cerebral oxygenation
timeFrame: Through study completion, an average of 2 weeks
measure: Number of repetitions performed in 1 set at 65%1RM until task failure
timeFrame: Through study completion, an average of 2 weeks
measure: Bar velocity deplacement performed in 1 set at 65%1RM until task failure
timeFrame: Through study completion, an average of 2 weeks
measure: Power output generated in 1 set at 65%1RM until task failure
timeFrame: Through study completion, an average of 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Alcalá de Henares
country: Spain
facility: Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
state: Madrid
Study officials:
References:
Clinical trial NCT03718676: Pulpotomy With Various MTA Materials and Ferric Sulphate
Official title: Clinical and Radiographic Comparison of RetroMTA, OrthoMTA And Ferric Sulfate for Pulpotomy in Primary Molars
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pulpotomy
Keywords: pulpotomy
Lead sponsor: Aydin Adnan Menderes University
Sponsor class: OTHER
First posted: 2018-10-24
Enrollment: 32
Sex: ALL
Minimum age (years): 5
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study was to determine clinical and radiographic efficacy of the newly developed OrthoMTA and RetroMTA , compared frequently used ferric sulfate for pulpotomy in primary second molars.

Detailed description: A total of 96 second primary second molars from 32 children ,who met inclusion criteria and were 5-9 years old were selected for the study. Teeth were randomly divided into three groups according to the planned treatment: O-MTA (n=32 teeth), R-MTA (n=32 teeth) and FS (n=32 teeth). Clinical and radiographical follow-up examinations were conducted at 3, 6 and 9 months postoperatively. The data were evaluated with Chi-square test, Cochran Q test, Post-Huc Dunn test and Kaplan-Meier analysis.

Eligibility criteria: Inclusion Criteria:

* Patients have at least three deep carious primary second molars
* Teeth with no spontaneous pain
* Patient who are willing to participate
* Cooperative children

Exclusion Criteria:

* Patients who are not willing to participate
* History of systemic disease
* Pathological mobility
* Presence of internal or external root resorption
* Presence of apical radiolucency

Primary outcomes:
measure: Clinical success rate
timeFrame: Change of clinical success from Baseline at 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Aydin
country: Turkey
facility: Sultan KELES
Study officials:
affiliation: Pediatric dentistry
name: sultan keles, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Awawdeh L, Al-Qudah A, Hamouri H, Chakra RJ. Outcomes of Vital Pulp Therapy Using Mineral Trioxide Aggregate or Biodentine: A Prospective Randomized Clinical Trial. J Endod. 2018 Nov;44(11):1603-1609. doi: 10.1016/j.joen.2018.08.004. Epub 2018 Oct 3.
Clinical trial NCT04164576: Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients
Official title: Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Renal-urinary Impairment
Graft Rejection
Infection Episodes
Keywords: Lung transplantation
BKV
Nephropathy
Immunosuppression
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2019-11-15
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Lung transplant recipients between 30 June 2018 and 31 December 2022 at the University Hospital of Strasbourg

Brief summary: BK virus (BKV) is a ubiquitous virus that infects more than 80% of the population. In case of immunosuppression, BKV can replicate and induce nephropathies in renal transplant recipients or haemorrhagic cystitis in bone marrow transplant recipients. The disruption of the balance between BKV replication and immune control is considered the key element in the development of these pathologies. During lung transplantation, patients undergo intense immunosuppression that favors the reactivation of persistent viruses such as EBV, CMV and probably BKV. Although the data on EBV and CMV reactivation are very clear and allow optimal management, the prevalence of BKV replication and its clinical impact in lung transplant recipients remains unknown at this time.

The aim of this study is to know the incidence and clinical impact of BKV replication in lung transplant recipients. Moreover, the results will help to better understand the interaction between the virus and his host, with a focus on the humoral and cellular immune response against BKV. The results could possibly enable to define predictive markers of BKV replication and of its evolution.


Eligibility criteria: Inclusion criteria:

* Lung transplant recipients in Strasbourg University Hospital between 30 June 2018 and 31 December 2022
* Male or female patients, age over 18 years
* Patient having provided informed written consent to take part in the study
* Patient affiliated to Social Security

Exclusion criteria:

* Patient deprived of liberty, by judicial or administrative decision
* Patient under legal guardianship
* Impossibility to give complete information about this study to the patient

Primary outcomes:
measure: BKV viral load in urine (viruria) and in plasma (viremia)
timeFrame: 3 years
Secondary outcomes:
measure: Quantification of anti-BKV neutralizing antibodies
timeFrame: 3 years
Other outcomes:
measure: Quantification of BKV specific T lymphocytes
timeFrame: 3 years
measure: TTV viral load in plasma
timeFrame: 3 years
Locations:
city: Strasbourg
country: France
facility: Les Hôpitaux Universitaires de Strasbourg
Study officials:
References:
Clinical trial NCT06686576: A Study of Perioperative QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Official title: A Phase Ib/III, Open-Label, Randomized Study of Perioperative QL1706 Versus Standard of Care in Participants With Untreated of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Colon Cancer
Lead sponsor: Qilu Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-11-13
Enrollment: 288
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to evaluate the efficacy of perioperative QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer


Eligibility criteria: Inclusion Criteria:

* Signed written informed consent;
* Eastern Cooperative Oncology Group Performance Status of 0 or 1
* Untreated pathologically confirmed colon adenocarcinoma
* Radiographic assessment showed a resectable stage IIB-III based on AJCC Stage VIII (cT4 or cN+ only).
* Has a tumor demonstrating the presence of MSI-H/ dMMR
* Adequate organ function as described in the protocol

Exclusion Criteria:

* Previously received any antitumor therapy for the disease under study, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc
* Has distant metastatic disease.
* Has an active autoimmune disease that has required systemic treatment in past 2 years
* Has know history of, or any evidence of interstitial lung disease;
* Has an active infection requiring systemic therapy

Primary outcomes:
measure: Pathological Complete Response(pCR), defined as the proportion of subjects with no residual tumor in the primary tumor removed and in all lymph nodes removed after neoadjuvant therapy.
timeFrame: 1 month after surgery
measure: Event Free Survival, EFS(EFS), defined as the time from randomization to either disease recurrence or death due to any cause or treatment related toxicity that results in the participant not being suitable for surgery.
timeFrame: Up to approximately 5 years
Secondary outcomes:
measure: Overall Survival (OS)
timeFrame: Up to approximately 5 years
measure: R0 tumor resection rate
timeFrame: 2 week after surgery
measure: Number of Participants with treatment emergent adverse events (AEs), serious adverse events (SAEs), Immune-mediated Adverse Event (imAEs), AEs leading to death and AEs leading to discontinuation of study treatment
timeFrame: Up to approximately 5 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Affiliated Cancer Hospital of Sun Yat-sen University
Study officials:
References:
Clinical trial NCT05051176: Prevalence of Diastasis m. Rectus Abdominis in Postpartum Women
Official title: Prevalence of Diastasis m. Rectus Abdominis and Pelvic Floor Muscle Dysfunction in Postpartum Women
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diastasis of m. Rectus Abdominis
Lead sponsor: Pavol Jozef Safarik University
Sponsor class: OTHER
First posted: 2021-09-21
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women from six weeks to up to 6 months after birth, age over 18 years old.

Brief summary: This study will evaluate the prevalence of diastasis m. rectus abdominis after delivery.

Relationship of Diastasis Recti Abdominis with urine leakage, pelvic floor muscle function and morphometry in postpartum women.

Detailed description: Evaluation of the width of the linea alba within the evaluation of diastasis of the rectus abdominis by 2D USG relation to pelvic floor muscle function (strength and endurance of pelvic floor muscles) and pelvic floor muscle morphometry by 3D/4D USG .

Eligibility criteria: Inclusion Criteria:

* Women from six weeks to up to 6 months after birth, age over 18 years old.

Exclusion Criteria:

* Psychiatric illness, postpartum depression, non-cooperation. Neurological diseases conditions after a stroke, a history of brain injury, significant visual and hearing damage, confirmed by neurological examination. Serious internal, orthopedic and oncological diseases. Disagreement with inclusion in the study.

Primary outcomes:
measure: Prevalence of Diastasis Recti Abdominis in Postpartum Women.
timeFrame: Six weeks to up to 6 months after birth
Secondary outcomes:
measure: Relationship of Diastasis Recti Abdominis with urine leakage, pelvic floor muscle function and morphometry in postpartum women.
timeFrame: Six weeks to up to 6 months after birth.
measure: Relationship between Diastasis Recti Abdominis and back pain in postpartum women.
timeFrame: Six weeks to up to 6 months after birth.
Other outcomes:
Locations:
city: Košice
country: Slovakia
facility: PJ Safarik University
Study officials:
affiliation: Department of Gynecology and Obstetrics, Medical Faculty, PJ Safarik University, Kosice, Slovakia
name: Rastislav Dudič, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: KFBLR, Medical Faculty, PJ Safarik University, Kosice, Slovakia
name: Magdalena Hagovska, Prof,PhD
role: STUDY_DIRECTOR
affiliation: Department of Urology, Institution, Comenius University Bratislava, Slovakia
name: Jan Svihra, Prof,MD,PhD.
role: STUDY_DIRECTOR
References:
Clinical trial NCT04584476: Superior Capsular Reconstruction Versus. Partial Repair for Irreparable Rotator Cuff Tears
Official title: Superior Capsular Reconstruction Versus. Partial Repair for Irreparable Rotator Cuff Tears: A Prospective Comparative Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rotator Cuff Tears
Keywords: Irreparable Rotator Cuff Tears
Superior Capsular Reconstruction
Lead sponsor: Beijing Jishuitan Hospital
Sponsor class: OTHER
First posted: 2020-10-14
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Rotator cuff tear is one of the common injuries that cause shoulder pain in the elderly. After the rotator cuff tendon is injured, repairing the torn rotator cuff tendon through arthroscopic surgery is an effective treatment that is currently widely used. In the rotator cuff injury, irreparable rotator cuff injury is a difficult point in treatment, especially for patients with a long injury time, the obvious shrinkage of the injured tendon, muscle atrophy and steatosis may occur, all of which lead to the poor quality of the rotator cuff tendon needed to be repaired , Poor healing ability, seriously affecting the shoulder joint function and daily life of these patients. For this part of patients, arthroscopic partial repair of torn rotator cuffs is one of the commonly used methods. In addition, in recent years, superior capsular reconstruction has been gradually applied to the clinic and has achieved good clinical effects, but there are no controlled studies to compare Clinical effect of partial repair and superior capsular reconstruction on irreparable rotator cuff injury.


Eligibility criteria: Inclusion Criteria:

* patients with Irreparable Rotator Cuff Tears
* underwent superior capsular reconstruction or partial repair
* at least two years follow-up

Exclusion Criteria:

* reparable Rotator Cuff Tears
* underwent reverse total shoulder arthroplasty

Primary outcomes:
measure: American Shoulder and Elbow Surgeons (ASES) score
timeFrame: 2 year postoperatively
measure: Acromiohumeral distance (AHD)
timeFrame: 1 year postoperatively
measure: retear rate
timeFrame: 1 year postoperatively
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Sports Medicine Service, Beijing Jishuitan hospital
name: Chunyan Jiang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05441176: TULIP et MASC : Premiers Usages
Official title: TULIP et MASC : Premiers Usages
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Thoracic Outlet Syndrome
Keywords: suspicion of arterial TOS and/or veinous TOS
DASH questionnaire
TULIP and MASC questionnaires
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2022-07-01
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The aim of this work is to propose two new questionnaires (TULIP and MASC) which are simple to complete by the patient, quick to analyze and can be calculated directly by the physician, adapted to the general population, whether during an initial evaluation or for follow-up.

The TULIP questionnaire aims to characterize the symptoms suggestive of Thoracic Outlet Syndrome (TOS). The MASC questionnaire aims to assess the functional maintenance of TOS in a simpler way (fewer questions) than the Disability of the Arm, Shoulder and Hand (DASH) questionnaire and in a lateralized way.

Detailed description: Two questionnaires the TULIP and the MASC are submitted (self completion) to patients suspected of TOS.

Eligibility criteria: Inclusion Criteria:

* Suspicion of Thoracic Outlet Syndrome

Exclusion Criteria:

Non applicable

Primary outcomes:
measure: Feasibility of both questionnaires : percentage of questionnaires correctly completed
timeFrame: 1 day
Secondary outcomes:
measure: TULIP : Diagnostic performance of vascular TOS by concordance between each response and vascular investigations results evaluation
timeFrame: 1 day
measure: MASC : Concording with DASH questionnaire
timeFrame: 1 day
measure: MASC : Comparison between concordance MASC/DASH and concordance MASC/Quick DASH
timeFrame: 1 day
Other outcomes:
Locations:
city: Angers
country: France
facility: University Hospital
Study officials:
References:
Clinical trial NCT05283876: Excimer Light in Psoriasis
Official title: Excimer Light Effect on Neurogenic Inflammation in Developing Versus Stationary Psoriasis Lesions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Psoriasis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-03-17
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine the standard tissue levels of SP and its receptor in lesional skin of psoriasis patients in both developing and stationary stages before and after excimer light therapy.


Eligibility criteria: Inclusion Criteria:

* Type of Psoriasis: plaque psoriasis.
* Less than 10% surface area.

Exclusion Criteria:

* Erythrodermic psoriasis
* Pustular psoriasis
* Topical treatment for psoriasis for the past 2 weeks.
* Systemic retinoids in the last 2 years.
* Systemic treatments (including any drugs that affect SP level as Aprepitant) in the last 3 months.
* Contraindications to excimer light therapy (history of skin malignancy or precancerous conditions like xeroderma pigmentosum or photosensitivity)

Primary outcomes:
measure: Excimer laser efficiency in active and stable psoriasis
timeFrame: through study completion, an average of 6 months
measure: Excimer laser efficiency on neurogenic inflammation
timeFrame: through study completion, an average of 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr Al Ainy Faculty of medicine
Study officials:
References: